10:41:46 EDT Mon 23 May 2022
Enter Symbol
or Name

Login ID:
Doseology Sciences Inc
Symbol MOOD
Shares Issued 41,100,300
Close 2022-01-27 C$ 0.17
Recent Sedar Documents

Doseology Sciences appoints Geh as CFO

2022-01-28 10:39 ET - News Release

Ms. Maryam Marissen reports


Doseology Sciences Inc. has appointed Peter Geh as chief financial officer, effective Jan. 26, 2022, and has added Harbir Toor as director and independent audit chair, effective Jan. 27, 2022.

Mr. Geh is an experienced financial and accounting executive based in Kelowna, B.C. As a chartered professional accountant with over 15 years of corporate experience, he has guided several Canadian companies through growth stages in the healthtech, retail and manufacturing industries.

Mr. Geh spent over 10 years in public practice accounting working with entities in the public, private and not-for-profit sectors. As vice-president, finance, of a Canadian tech company, Mr. Geh oversaw revenue growth of over 400 per cent and staff growth of 75 per cent during a two-year period.

"We're very fortunate to have Peter join our team at this critical stage," said Maryam Marissen, Doseology chief executive officer. "His experience across several related industries in British Columbia, plus his ability to hone in on financial details while maintaining high-level perspective, make him the ideal CFO for Doseology."

On the appointment, Mr. Geh remarked: "I am very excited about the opportunity to be a part of such an innovative, growing company like Doseology. To help guide us forward, I plan to leverage my specialties in strategic planning and execution, financial risk management and shareholder value creation. I have a passion for helping companies of this size because I can take a very hands-on approach to financial management. I'm looking forward to working towards our goals with the Doseology team."

Doseology has also named Ms. Toor, CPA, CA, as the independent audit chair of the board of directors. Ms. Toor has 25 years of experience in strategic planning, risk management, governance, capital raises and financial accounting. She began her career in audit at KPMG and most recently has held several senior executive positions in both private and publicly listed companies, including vice-president, finance, and CFO in the biopharmaceutical and life sciences industries.

CEO Ms. Marissen commented: "Harbir is a tremendous asset for a diversified life sciences company such as ours. She has guided several other Canadian biotech and pharmaceutical companies in their financial and operational growth phases, and that relevant experience is truly invaluable."

Ms. Marissen thanks interim CFO Alex McAulay for his service to the company. Doseology also announces that Gordon Jang has resigned as a director and independent audit chair of the company, effective Jan. 27, 2022. Mr. Jang will remain an adviser on Doseology's financial matters and strategic decisions. Doseology wishes to thank Mr. Jang for his valuable service and insight.

To support the company's mission and create profitable revenue streams in growing markets, Doseology is pursuing the cultivation of functional mushrooms, distribution of its medicinal mushroom nootropics products and establishing clinical services. In November, the company applied for a Health Canada dealer's licence, which upon approval will allow for psilocybin-related research and cultivation.

About Doseology Sciences Inc.

Doseology is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.